| Alternative therapies are needed for patients with psoriasis who must discontinue a tumor necrosis factor alpha (TNF-α) inhibitor due to limited efficacy, loss of efficacy, or adverse reactions. |
| In patients switched to ixekizumab following non-response to etanercept, a TNF-α inhibitor, we observed a favorable response in the majority of patients. |
| In both UNCOVER-2 and -3, safety profiles were comparable in placebo non-responders and etanercept non-responders after switching to ixekizumab. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.